Pharmacotherapy of Critical Asthma Syndrome: Current and Emerging Therapies

Clinical Reviews in Allergy and Immunology

Volumn 48, Issue 1, 2015, Pages 7-30

  Albertson, T E ^a,b,c   Schivo, M ^a   Gidwani, N ^a,b   Kenyon, N J ^a   Sutter, M E ^a,b   Chan, A L ^a,b   Louie, S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA NORTHERN CALIFORNIA HEALTH CARE SYSTEM   (United States)

^c Pulmonary and Critical Care Medicine   (United States)

Author keywords

Asthma; Asthma treatment; Asthma chronic obstructive pulmonary disease overlap syndrome (ACOS); Beta2 agonists; Corticosteroids; Critical asthma syndrome (CAS); Cromolyn; Inhaled corticosteroids; Leukotriene modifiers; Muscarinic antagonists; Omalizumab; Roflumilast; Theophylline

Indexed keywords

ANTIASTHMATIC AGENT; ANTIIDIOTYPIC ANTIBODY; IMMUNOGLOBULIN E; MONOCLONAL ANTIBODY; OMALIZUMAB;

ANIMAL; ASTHMA; CRITICAL ILLNESS; DRUG EFFECTS; EXPERT WITNESS; HUMAN; IMMUNOLOGY; IMMUNOMODULATION; METABOLISM; PRACTICE GUIDELINE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY SYSTEM; SYNDROME; TRENDS;

ANIMALS; ANTI-ASTHMATIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; ASTHMA; CRITICAL ILLNESS; DRUG THERAPY; EXPERT TESTIMONY; HUMANS; IMMUNOGLOBULIN E; IMMUNOMODULATION; PRACTICE GUIDELINES AS TOPIC; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY SYSTEM; SYNDROME;

EID: 84886735709     PISSN: 10800549     EISSN: 15590267     Source Type: Journal    
DOI: 10.1007/s12016-013-8393-8     Document Type: Review

References (255)

1. Bateman ED, Hurd SS, Barnes PJ et al (2008) Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 31:143–178
2. National Asthma Education and Prevention Program (2007) National Heart, Lung and Blood Institute. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. Available from http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf
3. Lin TY, Poon AH, Hamid Q (2013) Asthma phenotypes and endotypes. Curr Opin Pulm Med 19:18–23
4. Murata A, Ling PM (2012) Asthma diagnosis and management. Emerg Med Clin North Am 30:203–222, vii
5. Agache I, Akdis C, Jutel M, Virchow JC (2012) Untangling asthma phenotypes and endotypes. Allergy 67:835–846
6. Louie S, Zeki AA, Schivo M et al (2013) The asthma-chronic obstructive pulmonary disease overlap syndrome: pharmacotherapeutic considerations. Expert Rev Clin Pharmacol 6:197–219
7. Miravitlles M, Soriano JB, Ancochea J et al (2013) Characterisation of the overlap COPD-asthma phenotype. Focus on physical activity and health status. Respir Med 107:1053–1060
8. de Marco R, Pesce G, Marcon A et al (2013) The coexistence of asthma and chronic obstructive pulmonary disease (COPD): prevalence and risk factors in young, middle-aged and elderly people from the general population. PLoS One 8:e62985
9. McDonald VM, Higgins I, Gibson PG (2013) Insight into older peoples’ healthcare experiences with managing COPD, asthma, and asthma-COPD overlap. J Asthma 50:497–504
10. Zeki AA, Schivo M, Chan A, Albertson TE, Louie S (2011) The asthma-COPD overlap syndrome: a common clinical problem in the elderly. J Allergy (Cairo) 2011:861926
11. Lougheed MD, Lemiere C, Dell SD et al (2010) Canadian Thoracic Society Asthma Management Continuum—2010 Consensus Summary for children six years of age and over, and adults. Can Respir J 17:15–24
12. Bacharier LB, Guilbert TW (2012) Diagnosis and management of early asthma in preschool-aged children. J Allergy Clin Immunol 130:287–296, quiz 297–288
13. Cazzola M, Page CP, Rogliani P, Matera MG (2013) Beta2-agonist therapy in lung disease. Am J Respir Crit Care Med 187:690–696
14. Dhuper S, Chandra A, Ahmed A et al (2011) Efficacy and cost comparisons of bronchodilatator administration between metered dose inhalers with disposable spacers and nebulizers for acute asthma treatment. J Emerg Med 40:247–255
15. Cates, C.J., Crilly, J.A. and Rowe, B.H. (2006) Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma. Cochrane Database Syst Rev. CD000052
16. Rodrigo GJ, Rodrigo C (2002) Continuous vs intermittent beta-agonists in the treatment of acute adult asthma: a systematic review with meta-analysis. Chest 122:160–165
17. Camargo, C.A., Jr., Spooner, C.H. and Rowe, B.H. (2003) Continuous versus intermittent beta-agonists in the treatment of acute asthma. Cochrane Database Syst Rev. CD001115
18. Walters, E.H. and Walters, J. (2000) Inhaled short acting beta2-agonist use in asthma: regular vs as needed treatment. Cochrane Database Syst Rev. CD001285
19. Travers AH, Rowe BH, Barker S, Jones A, Camargo CA Jr (2002) The effectiveness of IV beta-agonists in treating patients with acute asthma in the emergency department: a meta-analysis. Chest 122:1200–1207
20. Travers AH, Milan SJ, Jones AP, Camargo CA Jr, Rowe BH (2012) Addition of intravenous beta(2)-agonists to inhaled beta(2)-agonists for acute asthma. Cochrane Database Syst Rev 12:CD010179
21. Travers AH, Jones AP, Camargo CA Jr, Milan SJ, Rowe BH (2012) Intravenous beta(2)-agonists versus intravenous aminophylline for acute asthma. Cochrane Database Syst Rev 12:CD010256
22. Cochrane GM, Clark TJ, Hanan ME (1973) The role of oral bronchodilator therapy as shown by a comparison between salbutamol and terbutaline. Curr Med Res Opin 1:517–523
23. Harris L (1973) Comparison of cardiorespiratory effects of terbutaline and salbutamol aerosols in patients with reversible airways obstruction. Thorax 28:592–595
24. Adoun M, Frat JP, Dore P, Rouffineau J, Godet C, Robert R (2004) Comparison of nebulized epinephrine and terbutaline in patients with acute severe asthma: a controlled trial. J Crit Care 19:99–102
25. Abroug F, Nouira S, Bchir A, Boujdaria R, Elatrous S, Bouchoucha S (1995) A controlled trial of nebulized salbutamol and adrenaline in acute severe asthma. Intensive Care Med 21:18–23
26. Spiteri MA, Millar AB, Pavia D, Clarke SW (1988) Subcutaneous adrenaline versus terbutaline in the treatment of acute severe asthma. Thorax 43:19–23
27. Ayres J, Fish DR, Wheeler DC, Wiggins J, Cochrane GM, Skinner C (1984) Subcutaneous terbutaline and control of brittle asthma or appreciable morning dipping. Br Med J (Clin Res Ed) 288:1715–1716
28. Payne DN, Balfour-Lynn IM, Biggart EA, Bush A, Rosenthal M (2002) Subcutaneous terbutaline in children with chronic severe asthma. Pediatr Pulmonol 33:356–361
29. Donohue JF (2004) Therapeutic responses in asthma and COPD. Bronchodilators. Chest 126:125S–137S, discussion 159S–161S
30. Nishiyama O, Taniguchi H, Kondoh Y et al (2006) Comparison of the effects of tulobuterol patch and salmeterol in moderate to severe asthma. Clin Exp Pharmacol Physiol 33:1016–1021
31. Mochizuki H, Nanjo Y, Takahashi H (2013) Better adherence to a transdermal tulobuterol patch than inhaled salmeterol in elderly chronic obstructive pulmonary disease patients. Geriatr Gerontol Int 13:398–404
32. Katsunuma T, Ohya Y, Fujisawa T et al (2012) Effects of the tulobuterol patch on the treatment of acute asthma exacerbations in young children. Allergy Asthma Proc 33:e28–e34
33. Israel E, Chinchilli VM, Ford JG et al (2004) Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet 364:1505–1512
34. Israel E, Drazen JM, Liggett SB et al (2001) Effect of polymorphism of the beta(2)-adrenergic receptor on response to regular use of albuterol in asthma. Int Arch Allergy Immunol 124:183–186
35. Tattersfield AE, Hall IP (2004) Are beta2-adrenoceptor polymorphisms important in asthma–an unravelling story. Lancet 364:1464–1466
36. Johnson M (2006) Molecular mechanisms of beta(2)-adrenergic receptor function, response, and regulation. J Allergy Clin Immunol 117:18–24, quiz 25
37. Dodda VR, Spiro P (2012) Can albuterol be blamed for lactic acidosis? Respir Care 57:2115–2118
38. Sykes DA, Charlton SJ (2012) Slow receptor dissociation is not a key factor in the duration of action of inhaled long-acting beta2-adrenoceptor agonists. Br J Pharmacol 165:2672–2683
39. Patel S, Summerhill S, Stanley M, Perros-Huguet C, Trevethick MA (2011) The reassertion profiles of long acting beta2-adrenoceptor agonists in the guinea pig isolated trachea and human recombinant beta2-adrenoceptor. Pulm Pharmacol Ther 24:247–255
40. Cheung D, Timmers MC, Zwinderman AH, Bel EH, Dijkman JH, Sterk PJ (1992) Long-term effects of a long-acting beta 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. N Engl J Med 327:1198–1203
41. Greenstone, I.R., Ni Chroinin, M.N., Masse, V., et al. (2005) Combination of inhaled long-acting beta2-agonists and inhaled steroids versus higher dose of inhaled steroids in children and adults with persistent asthma. Cochrane Database Syst Rev. CD005533
42. Castro-Rodriguez JA, Rodrigo GJ (2012) A systematic review of long-acting beta2-agonists versus higher doses of inhaled corticosteroids in asthma. Pediatrics 130:e650–e657
43. Ni Chroinin, M., Greenstone, I., Lasserson, T.J. and Ducharme, F.M. (2009) Addition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults and children. Cochrane Database Syst Rev. CD005307
44. Suissa S, Ariel A (2013) US Food and Drug Administration-mandated trials of long-acting beta-agonists safety in asthma: will we know the answer? Chest 143:1208–1213
45. Castle W, Fuller R, Hall J, Palmer J (1993) Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ 306:1034–1037
46. Spitzer WO, Suissa S, Ernst P et al (1992) The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med 326:501–506
47. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM, Group, S.S (2006) The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 129:15–26
48. Salpeter SR, Buckley NS, Ormiston TM, Salpeter EE (2006) Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med 144:904–912
49. Cates CJ, Oleszczuk M, Stovold E, Wieland LS (2012) Safety of regular formoterol or salmeterol in children with asthma: an overview of Cochrane reviews. Cochrane Database Syst Rev 10:CD010005
50. Weatherall M, Wijesinghe M, Perrin K, Harwood M, Beasley R (2010) Meta-analysis of the risk of mortality with salmeterol and the effect of concomitant inhaled corticosteroid therapy. Thorax 65:39–43
51. Kramer JM (2009) Balancing the benefits and risks of inhaled long-acting beta-agonists—the influence of values. N Engl J Med 360:1592–1595
52. Salpeter SR, Ormiston TM, Salpeter EE (2004) Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest 125:2309–2321
53. Bollmeier SG, Lee SY (2013) The emerging role of tiotropium for patients with asthma. Ann Pharmacother 47:704–713
54. Gelb AF, Karpel J, Wise RA, Cassino C, Johnson P, Conoscenti CS (2008) Bronchodilator efficacy of the fixed combination of ipratropium and albuterol compared to albuterol alone in moderate-to-severe persistent asthma. Pulm Pharmacol Ther 21:630–636
55. Lazarus SC (2010) Clinical practice. Emergency treatment of asthma. N Engl J Med 363:755–764
56. Teoh L, Cates CJ, Hurwitz M, Acworth JP, van Asperen P, Chang AB (2012) Anticholinergic therapy for acute asthma in children. Cochrane Database Syst Rev 4:CD003797
57. Plotnick, L.H. and Ducharme, F.M. (2000), Combined inhaled anticholinergics and beta2-agonists for initial treatment of acute asthma in children. Cochrane Database Syst Rev. CD000060
58. Rodrigo GJ, Castro-Rodriguez JA (2005) Anticholinergics in the treatment of children and adults with acute asthma: a systematic review with meta-analysis. Thorax 60:740–746
59. Rodrigo GJ, Rodrigo C (2000) First-line therapy for adult patients with acute asthma receiving a multiple-dose protocol of ipratropium bromide plus albuterol in the emergency department. Am J Respir Crit Care Med 161:1862–1868
60. Kerstjens HA, Engel M, Dahl R et al (2012) Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med 367:1198–1207
61. Peters SP, Kunselman SJ, Icitovic N et al (2010) Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med 363:1715–1726
62. Bateman ED, Kornmann O, Schmidt P, Pivovarova A, Engel M, Fabbri LM (2011) Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthma. J Allergy Clin Immunol 128:315–322
63. Michele TM, Pinheiro S, Iyasu S (2010) The safety of tiotropium—the FDA’s conclusions. N Engl J Med 363:1097–1099
64. Mathew J, Aronow WS, Chandy D (2012) Therapeutic options for severe asthma. Arch Med Sci 8:589–597
65. Chung KF, Caramori G, Adcock IM (2009) Inhaled corticosteroids as combination therapy with beta-adrenergic agonists in airways disease: present and future. Eur J Clin Pharmacol 65:853–871
66. Raissy HH, Kelly HW, Harkins M, Szefler SJ (2013) Inhaled corticosteroids in lung diseases. Am J Respir Crit Care Med 187:798–803
67. Yick CY, Zwinderman AH, Kunst PW et al (2013) Glucocorticoid-induced changes in gene expression of airway smooth muscle in patients with asthma. Am J Respir Crit Care Med 187:1076–1084
68. Newton R (2000) Molecular mechanisms of glucocorticoid action: what is important? Thorax 55:603–613
69. Castro-Rodriguez JA, Rodrigo GJ (2009) Efficacy of inhaled corticosteroids in infants and preschoolers with recurrent wheezing and asthma: a systematic review with meta-analysis. Pediatrics 123:e519–e525
70. Bacharier LB, Guilbert TW, Zeiger RS et al (2009) Patient characteristics associated with improved outcomes with use of an inhaled corticosteroid in preschool children at risk for asthma. J Allergy Clin Immunol 123:1077–1082, 1082 e1071-1075
71. Murray CS, Woodcock A, Langley SJ, Morris J, Custovic A, Team I.S. (2006) Secondary prevention of asthma by the use of Inhaled fluticasone propionate in wheezy infants (IFWIN): double-blind, randomised, controlled study. Lancet 368:754–762
72. Donahue JG, Weiss ST, Livingston JM, Goetsch MA, Greineder DK, Platt R (1997) Inhaled steroids and the risk of hospitalization for asthma. JAMA 277:887–891
73. Adams, N.P., Bestall, J.B., Malouf, R., Lasserson, T.J. and Jones, P.W. (2005), Inhaled beclomethasone versus placebo for chronic asthma. Cochrane Database Syst Rev. CD002738
74. Masoli M, Weatherall M, Holt S, Beasley R (2004) Clinical dose–response relationship of fluticasone propionate in adults with asthma. Thorax 59:16–20
75. Masoli M, Weatherall M, Holt S, Beasley R (2004) Systematic review of the dose–response relation of inhaled fluticasone propionate. Arch Dis Child 89:902–907
76. Bousquet J, Ben-Joseph R, Messonnier M, Alemao E, Gould AL (2002) A meta-analysis of the dose–response relationship of inhaled corticosteroids in adolescents and adults with mild to moderate persistent asthma. Clin Ther 24:1–20
77. Szefler SJ, Martin RJ, King TS et al (2002) Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol 109:410–418
78. Martin RJ, Szefler SJ, King TS et al (2007) The Predicting Response to Inhaled Corticosteroid Efficacy (PRICE) trial. J Allergy Clin Immunol 119:73–80
79. Anderson WJ, Short PM, Williamson PA, Lipworth BJ (2012) Inhaled corticosteroid dose response using domiciliary exhaled nitric oxide in persistent asthma: the FENOtype trial. Chest 142:1553–1561
80. Harrison TW, Oborne J, Newton S, Tattersfield AE (2004) Doubling the dose of inhaled corticosteroid to prevent asthma exacerbations: randomised controlled trial. Lancet 363:271–275
81. Reddel HK, Jenkins CR, Marks GB et al (2000) Optimal asthma control, starting with high doses of inhaled budesonide. Eur Respir J 16:226–235
82. Rank MA, Hagan JB, Park MA et al (2013) The risk of asthma exacerbation after stopping low-dose inhaled corticosteroids: a systematic review and meta-analysis of randomized controlled trials. J Allergy Clin Immunol 131:724–729
83. Ducharme, F.M., Ni Chroinin, M., Greenstone, I. and Lasserson, T.J. (2010), Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma. Cochrane Database Syst Rev. CD005533
84. Lazarus SC, Boushey HA, Fahy JV et al (2001) Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. JAMA 285:2583–2593
85. Ducharme, F.M., Lasserson, T.J. and Cates, C.J. (2011), Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma. Cochrane Database Syst Rev. CD003137
86. Lipworth BJ, Short PM, Williamson PA, Clearie KL, Fardon TC, Jackson CM (2012) A randomized primary care trial of steroid titration against mannitol in persistent asthma: STAMINA trial. Chest 141:607–615
87. Smith AD, Cowan JO, Brassett KP, Herbison GP, Taylor DR (2005) Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med 352:2163–2173
88. Jang AS (2012) Steroid response in refractory asthmatics. Korean J Intern Med 27:143–148
89. Barnes PJ (2013) Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease. J Allergy Clin Immunol 131:636–645
90. Adcock IM, Barnes PJ (2008) Molecular mechanisms of corticosteroid resistance. Chest 134:394–401
91. Sher ER, Leung DY, Surs W et al (1994) Steroid-resistant asthma. Cellular mechanisms contributing to inadequate response to glucocorticoid therapy. J Clin Invest 93:33–39
92. Boushey HA, Sorkness CA, King TS et al (2005) Daily versus as-needed corticosteroids for mild persistent asthma. N Engl J Med 352:1519–1528
93. Rodrigo, G.J. and Castro-Rodriguez, J.A. (2013) Daily vs. intermittent inhaled corticosteroids for recurrent wheezing and mild persistent asthma: a systematic review with meta-analysis. Respir Med (in press)
94. Chauhan BF, Chartrand C, Ducharme FM (2013) Intermittent versus daily inhaled corticosteroids for persistent asthma in children and adults. Cochrane Database Syst Rev 2:CD009611
95. Turpeinen M, Nikander K, Pelkonen AS et al (2008) Daily versus as-needed inhaled corticosteroid for mild persistent asthma (The Helsinki early intervention childhood asthma study). Arch Dis Child 93:654–659
96. Paggiaro P (2009) New pharmacologic perspectives in pneumology: beclomethasone-formoterol extrafine. Open Respir Med J 3:38–42
97. Scichilone N, Battaglia S, Sorino C et al (2010) Effects of extra-fine inhaled beclomethasone/formoterol on both large and small airways in asthma. Allergy 65:897–902
98. Barnes PJ, Nicolini G, Bizzi A, Spinola M, Singh D (2012) Do inhaled corticosteroid/long-acting beta2-agonist fixed combinations provide superior clinical benefits compared with separate inhalers? A literature reappraisal. Allergy Asthma Proc 33:140–144
99. Kramer S, Rottier BL, Scholten RJ, Boluyt N (2013) Ciclesonide versus other inhaled corticosteroids for chronic asthma in children. Cochrane Database Syst Rev 2:CD010352
100. Patel M, Perrin K, Pritchard A et al (2013) Accuracy of patient self-report as a measure of inhaled asthma medication use. Respirology 18:546–552
101. Murphy AC, Proeschal A, Brightling CE et al (2012) The relationship between clinical outcomes and medication adherence in difficult-to-control asthma. Thorax 67:751–753
102. Heaney LG, Horne R (2012) Non-adherence in difficult asthma: time to take it seriously. Thorax 67:268–270
103. Gamble J, Stevenson M, Heaney LG (2011) A study of a multi-level intervention to improve non-adherence in difficult to control asthma. Respir Med 105:1308–1315
104. Reddel HK, Barnes DJ, Exacerbation Advisory Panel (2006) Pharmacological strategies for self-management of asthma exacerbations. Eur Respir J 28:182–199
105. FitzGerald JM, Becker A, Sears MR et al (2004) Doubling the dose of budesonide versus maintenance treatment in asthma exacerbations. Thorax 59:550–556
106. Quon, B.S., Fitzgerald, J.M., Lemiere, C., Shahidi, N. and Ducharme, F.M. (2010) Increased versus stable doses of inhaled corticosteroids for exacerbations of chronic asthma in adults and children. Cochrane Database Syst Rev. CD007524
107. Rowe, B.H., Spooner, C.H., Ducharme, F.M., Bretzlaff, J.A. and Bota, G.W. (2007) Corticosteroids for preventing relapse following acute exacerbations of asthma. Cochrane Database Syst Rev. CD000195
108. Edmonds ML, Milan SJ, Camargo CA Jr, Pollack CV, Rowe BH (2012) Early use of inhaled corticosteroids in the emergency department treatment of acute asthma. Cochrane Database Syst Rev 12:CD002308
109. Rowe, B.H., Spooner, C., Ducharme, F.M., Bretzlaff, J.A. and Bota, G.W. (2001) Early emergency department treatment of acute asthma with systemic corticosteroids. Cochrane Database Syst Rev. CD002178
110. Smith, M., Iqbal, S., Elliott, T.M., Everard, M. and Rowe, B.H. (2003) Corticosteroids for hospitalised children with acute asthma. Cochrane Database Syst Rev. CD002886
111. Manser, R., Reid, D. and Abramson, M. (2001) Corticosteroids for acute severe asthma in hospitalised patients. Cochrane Database Syst Rev. CD001740
112. Harrison BD, Stokes TC, Hart GJ, Vaughan DA, Ali NJ, Robinson AA (1986) Need for intravenous hydrocortisone in addition to oral prednisolone in patients admitted to hospital with severe asthma without ventilatory failure. Lancet 1:181–184
113. Ratto D, Alfaro C, Sipsey J, Glovsky MM, Sharma OP (1988) Are intravenous corticosteroids required in status asthmaticus? JAMA 260:527–529
114. Dembla G, Mundle RP, Salkar HR, Doifoide DV (2011) Oral versus intravenous steroids in acute exacerbation of asthma—randomized controlled study. J Assoc Physicians India 59:621–623
115. Chan JS, Cowie RL, Lazarenko GC, Little C, Scott S, Ford GT (2001) Comparison of intramuscular betamethasone and oral prednisone in the prevention of relapse of acute asthma. Can Respir J 8:147–152
116. Schuckman H, DeJulius DP, Blanda M, Gerson LW, DeJulius AJ, Rajaratnam M (1998) Comparison of intramuscular triamcinolone and oral prednisone in the outpatient treatment of acute asthma: a randomized controlled trial. Ann Emerg Med 31:333–338
117. Gries DM, Moffitt DR, Pulos E, Carter ER (2000) A single dose of intramuscularly administered dexamethasone acetate is as effective as oral prednisone to treat asthma exacerbations in young children. J Pediatr 136:298–303
118. Lahn M, Bijur P, Gallagher EJ (2004) Randomized clinical trial of intramuscular vs oral methylprednisolone in the treatment of asthma exacerbations following discharge from an emergency department. Chest 126:362–368
119. Rowe BH, Bota GW, Fabris L, Therrien SA, Milner RA, Jacono J (1999) Inhaled budesonide in addition to oral corticosteroids to prevent asthma relapse following discharge from the emergency department: a randomized controlled trial. JAMA 281:2119–2126
120. Edmonds ML, Milan SJ, Brenner BE, Camargo CA Jr, Rowe BH (2012) Inhaled steroids for acute asthma following emergency department discharge. Cochrane Database Syst Rev 12:CD002316
121. Rossi GA, Cerasoli F, Cazzola M (2007) Safety of inhaled corticosteroids: room for improvement. Pulm Pharmacol Ther 20:23–35
122. Dahl R (2006) Systemic side effects of inhaled corticosteroids in patients with asthma. Respir Med 100:1307–1317
123. Martin RJ, Szefler SJ, Chinchilli VM et al (2002) Systemic effect comparisons of six inhaled corticosteroid preparations. Am J Respir Crit Care Med 165:1377–1383
124. Shepherd, J., Rogers, G., Anderson, R., et al. (2008) Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in adults and children aged 12 years and over. Health Technol Assess. 12, iii–iv, 1–360
125. Patel M, Pilcher J, Pritchard A et al (2013) Efficacy and safety of maintenance and reliever combination budesonide-formoterol inhaler in patients with asthma at risk of severe exacerbations: a randomised controlled trial. Lancet Respir Med 1:32–42
126. Rogers L, Reibman J (2011) Pharmacologic approaches to life-threatening asthma. Ther Adv Respir Dis 5:397–408
127. Blake KV (1999) Montelukast: data from clinical trials in the management of asthma. Ann Pharmacother 33:1299–1314
128. Yuksel B, Aydemir C, Ustundag G et al (2009) The effect of treatment with montelukast on levels of serum interleukin-10, eosinophil cationic protein, blood eosinophil counts, and clinical parameters in children with asthma. Turk J Pediatr 51:460–465
129. Bisgaard H, Nielsen KG (2000) Bronchoprotection with a leukotriene receptor antagonist in asthmatic preschool children. Am J Respir Crit Care Med 162:187–190
130. Garcia Garcia ML, Wahn U, Gilles L, Swern A, Tozzi CA, Polos P (2005) Montelukast, compared with fluticasone, for control of asthma among 6- to 14-year-old patients with mild asthma: the MOSAIC study. Pediatrics 116:360–369
131. Zeiger RS, Bird SR, Kaplan MS et al (2005) Short-term and long-term asthma control in patients with mild persistent asthma receiving montelukast or fluticasone: a randomized controlled trial. Am J Med 118:649–657
132. Zeiger RS, Szefler SJ, Phillips BR et al (2006) Response profiles to fluticasone and montelukast in mild-to-moderate persistent childhood asthma. J Allergy Clin Immunol 117:45–52
133. Busse W, Raphael GD, Galant S et al (2001) Low-dose fluticasone propionate compared with montelukast for first-line treatment of persistent asthma: a randomized clinical trial. J Allergy Clin Immunol 107:461–468
134. Malmstrom K, Rodriguez-Gomez G, Guerra J et al (1999) Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group. Ann Intern Med 130:487–495
135. Ducharme FM, Noya FJ, Allen-Ramey FC, Maiese EM, Gingras J, Blais L (2012) Clinical effectiveness of inhaled corticosteroids versus montelukast in children with asthma: prescription patterns and patient adherence as key factors. Curr Med Res Opin 28:111–119
136. Szefler SJ, Phillips BR, Martinez FD et al (2005) Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol 115:233–242
137. Jenkins CR, Thien FC, Wheatley JR, Reddel HK (2005) Traditional and patient-centred outcomes with three classes of asthma medication. Eur Respir J 26:36–44
138. Jartti T (2008) Inhaled corticosteroids or montelukast as the preferred primary long-term treatment for pediatric asthma? Eur J Pediatr 167:731–736
139. Price D, Popov TA, Bjermer L et al (2013) Effect of montelukast for treatment of asthma in cigarette smokers. J Allergy Clin Immunol 131:763–771
140. Lipworth BJ, Basu K, Donald HP et al (2013) Tailored second-line therapy in asthmatic children with the Arg(16) genotype. Clin Sci (Lond) 124:521–528
141. Cuevas Hernandez MM, Arias Hernandez RM (2004) Therapeutic effects of an antileukotriene in children with moderate-severe persistent asthma. Rev Alerg Mex 51:206–209
142. Cakmak G, Demir T, Gemicioglu B, Aydemir A, Serdaroglu E, Donma O (2004) The effects of add-on zafirlukast treatment to budesonide on bronchial hyperresponsiveness and serum levels of eosinophilic cationic protein and total antioxidant capacity in asthmatic patients. Tohoku J Exp Med 204:249–256
143. Matsuse H, Fukahori S, Tsuchida T et al (2012) Effects of a short course of pranlukast combined with systemic corticosteroid on acute asthma exacerbation induced by upper respiratory tract infection. J Asthma 49:637–641
144. Bleecker ER, Welch MJ, Weinstein SF et al (2000) Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma. J Allergy Clin Immunol 105:1123–1129
145. Busse W, Wolfe J, Storms W et al (2001) Fluticasone propionate compared with zafirlukast in controlling persistent asthma: a randomized double-blind, placebo-controlled trial. J Fam Pract 50:595–602
146. Nathan RA, Bleecker ER, Kalberg C, Fluticasone Propionate Study, G (2001) A comparison of short-term treatment with inhaled fluticasone propionate and zafirlukast for patients with persistent asthma. Am J Med 111:195–202
147. Brabson JH, Clifford D, Kerwin E et al (2002) Efficacy and safety of low-dose fluticasone propionate compared with zafirlukast in patients with persistent asthma. Am J Med 113:15–21
148. Twaites BR, Wilton LV, Shakir SA (2007) Safety of zafirlukast: results of a postmarketing surveillance study on 7976 patients in England. Drug Saf 30:419–429
149. Watts K, Chavasse RJ (2012) Leukotriene receptor antagonists in addition to usual care for acute asthma in adults and children. Cochrane Database Syst Rev 5:CD006100
150. Lazarus SC, Lee T, Kemp JP et al (1998) Safety and clinical efficacy of zileuton in patients with chronic asthma. Am J Manag Care 4:841–848
151. Kubavat AH, Khippal N, Tak S et al (2013) A randomized, comparative, multicentric clinical trial to assess the efficacy and safety of zileuton extended-release tablets with montelukast sodium tablets in patients suffering from chronic persistent asthma. Am J Ther 20:154–162
152. O’Connor BJ, Lofdahl CG, Balter M, Szczeklik A, Boulet LP, Cairns CB (2007) Zileuton added to low-dose inhaled beclomethasone for the treatment of moderate to severe persistent asthma. Respir Med 101:1088–1096
153. Gelb AF, Taylor CF, Simmons M, Shinar C (2009) Role of add-on zileuton on total exhaled, large airway, and small airway/alveolar nitric oxide in moderate-severe persistent adult asthmatics on fluticasone 250 microg/Salmeterol 50 microg. Pulm Pharmacol Ther 22:516–521
154. Tantisira KG, Lima J, Sylvia J, Klanderman B, Weiss ST (2009) 5-lipoxygenase pharmacogenetics in asthma: overlap with Cys-leukotriene receptor antagonist loci. Pharmacogenet Genomics 19:244–247
155. Nelson H, Kemp J, Berger W et al (2007) Efficacy of zileuton controlled-release tablets administered twice daily in the treatment of moderate persistent asthma: a 3-month randomized controlled study. Ann Allergy Asthma Immunol 99:178–184
156. Chauhan BF, Ducharme FM (2012) Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database Syst Rev 5:CD002314
157. Garcia-Marcos L, Schuster A, Perez-Yarza EG (2003) Benefit-risk assessment of antileukotrienes in the management of asthma. Drug Saf 26:483–518
158. Wenzel S, Busse W, Calhoun W et al (2007) The safety and efficacy of zileuton controlled-release tablets as adjunctive therapy to usual care in the treatment of moderate persistent asthma: a 6-month randomized controlled study. J Asthma 44:305–310
159. Watkins PB, Dube LM, Walton-Bowen K, Cameron CM, Kasten LE (2007) Clinical pattern of zileuton-associated liver injury: results of a 12-month study in patients with chronic asthma. Drug Saf 30:805–815
160. Bush A, Saglani S (2010) Management of severe asthma in children. Lancet 376:814–825
161. Netzer NC, Kupper T, Voss HW, Eliasson AH (2012) The actual role of sodium cromoglycate in the treatment of asthma—a critical review. Sleep Breath 16:1027–1032
162. Adams RJ, Fuhlbrigge A, Finkelstein JA et al (2001) Impact of inhaled antiinflammatory therapy on hospitalization and emergency department visits for children with asthma. Pediatrics 107:706–711
163. Guevara, J.P., Ducharme, F.M., Keren, R., Nihtianova, S. and Zorc, J. (2006), Inhaled corticosteroids versus sodium cromoglycate in children and adults with asthma. Cochrane Database Syst Rev. CD003558
164. Tasche MJ, Uijen JH, Bernsen RM, de Jongste JC, van der Wouden JC (2000) Inhaled disodium cromoglycate (DSCG) as maintenance therapy in children with asthma: a systematic review. Thorax 55:913–920
165. van der Wouden, J.C., Uijen, J.H., Bernsen, R.M., Tasche, M.J., de Jongste, J.C. and Ducharme, F. (2008), Inhaled sodium cromoglycate for asthma in children. Cochrane Database Syst Rev. CD002173
166. Keller M, Schierholz J (2011) Have inadequate delivery systems hampered the clinical success of inhaled disodium cromoglycate? Time for reconsideration. Expert Opin Drug Deliv 8:1–17
167. Katayama H, Yokoyama A, Fujino S et al (1996) Near-death asthmatic reaction induced by disodium cromoglycate. Intern Med 35:976–978
168. Barnes, P.J. (2013) Theophylline. Am J Respir Crit Care Med. doi: 10.1164/rccm.201302-0388PP
169. Kidney J, Dominguez M, Taylor PM, Rose M, Chung KF, Barnes PJ (1995) Immunomodulation by theophylline in asthma. Demonstration by withdrawal of therapy. Am J Respir Crit Care Med 151:1907–1914
170. MacLeod D, Djukanovic R (1996) Low-dose theophylline: a new anti-inflammatory role in asthma management? Monaldi Arch Chest Dis 51:30–34
171. Jaffar ZH, Sullivan P, Page C, Costello J (1996) Low-dose theophylline modulates T-lymphocyte activation in allergen-challenged asthmatics. Eur Respir J 9:456–462
172. Huang SD, Yang J, Zhang SY, Tian LQ, Pan QH (2006) Clinical efficacy of low-dose oral theophylline for treating mild asthma. Nan Fang Yi Ke Da Xue Xue Bao 26:325–327
173. Lim S, Tomita K, Caramori G et al (2001) Low-dose theophylline reduces eosinophilic inflammation but not exhaled nitric oxide in mild asthma. Am J Respir Crit Care Med 164:273–276
174. Barnes PJ (2009) Histone deacetylase-2 and airway disease. Ther Adv Respir Dis 3:235–243
175. Nakano J, Yano T, Yamamura K et al (2006) Aminophilline suppress the release of chemical mediators in treatment of acute asthma. Respir Med 100:542–550
176. Yung M, South M (1998) Randomised controlled trial of aminophylline for severe acute asthma. Arch Dis Child 79:405–410
177. D’Avila RS, Piva JP, Marostica PJ, Amantea SL (2008) Early administration of two intravenous bolus of aminophylline added to the standard treatment of children with acute asthma. Respir Med 102:156–161
178. Wheeler DS, Jacobs BR, Kenreigh CA, Bean JA, Hutson TK, Brilli RJ (2005) Theophylline versus terbutaline in treating critically ill children with status asthmaticus: a prospective, randomized, controlled trial. Pediatr Crit Care Med 6:142–147
179. Littenberg B (1988) Aminophylline treatment in severe, acute asthma. A meta-analysis. JAMA 259:1678–1684
180. Parameswaran, K., Belda, J. and Rowe, B.H. (2000), Addition of intravenous aminophylline to beta2-agonists in adults with acute asthma. Cochrane Database Syst Rev. CD002742
181. Reed CE, Offord KP, Nelson HS, Li JT, Tinkelman DG (1998) Aerosol beclomethasone dipropionate spray compared with theophylline as primary treatment for chronic mild-to-moderate asthma. The American Academy of Allergy, Asthma and Immunology Beclomethasone Dipropionate-Theophylline Study Group. J Allergy Clin Immunol 101:14–23
182. Spears M, Donnelly I, Jolly L et al (2009) Effect of low-dose theophylline plus beclometasone on lung function in smokers with asthma: a pilot study. Eur Respir J 33:1010–1017
183. American Lung Association Asthma Clinical Research Center (2007) Clinical trial of low-dose theophylline and montelukast in patients with poorly controlled asthma. Am J Respir Crit Care Med 175:235–242
184. Tinkelman DG, Reed CE, Nelson HS, Offord KP (1993) Aerosol beclomethasone dipropionate compared with theophylline as primary treatment of chronic, mild to moderately severe asthma in children. Pediatrics 92:64–77
185. Evans DJ, Taylor DA, Zetterstrom O, Chung KF, O’Connor BJ, Barnes PJ (1997) A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. N Engl J Med 337:1412–1418
186. Dahl R, Larsen BB, Venge P (2002) Effect of long-term treatment with inhaled budesonide or theophylline on lung function, airway reactivity and asthma symptoms. Respir Med 96:432–438
187. Suessmuth S, Freihorst J, Gappa M (2003) Low-dose theophylline in childhood asthma: a placebo-controlled, double-blind study. Pediatr Allergy Immunol 14:394–400
188. Dombrowski MP, Schatz M, Wise R et al (2004) Randomized trial of inhaled beclomethasone dipropionate versus theophylline for moderate asthma during pregnancy. Am J Obstet Gynecol 190:737–744
189. Adachi M, Aizawa H, Ishihara K et al (2008) Comparison of salmeterol/fluticasone propionate (FP) combination with FP + sustained release theophylline in moderate asthma patients. Respir Med 102:1055–1064
190. Holimon TD, Chafin CC, Self TH (2001) Nocturnal asthma uncontrolled by inhaled corticosteroids: theophylline or long-acting beta2 agonists? Drugs 61:391–418
191. Yurdakul AS, Taci N, Eren A, Sipit T (2003) Comparative efficacy of once-daily therapy with inhaled corticosteroid, leukotriene antagonist or sustained-release theophylline in patients with mild persistent asthma. Respir Med 97:1313–1319
192. Seddon, P., Bara, A., Ducharme, F.M. and Lasserson, T.J. (2006) Oral xanthines as maintenance treatment for asthma in children. Cochrane Database Syst Rev. CD002885
193. Fan Chung K (2006) Phosphodiesterase inhibitors in airways disease. Eur J Pharmacol 533:110–117
194. Page CP, Spina D (2012) Selective PDE inhibitors as novel treatments for respiratory diseases. Curr Opin Pharmacol 12:275–286
195. Hatzelmann A, Morcillo EJ, Lungarella G et al (2010) The preclinical pharmacology of roflumilast—a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Pulm Pharmacol Ther 23:235–256
196. van Schalkwyk E, Strydom K, Williams Z et al (2005) Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactions. J Allergy Clin Immunol 116:292–298
197. Louw C, Williams Z, Venter L et al (2007) Roflumilast, a phosphodiesterase 4 inhibitor, reduces airway hyperresponsiveness after allergen challenge. Respiration 74:411–417
198. Gauvreau GM, Boulet LP, Schmid-Wirlitsch C et al (2011) Roflumilast attenuates allergen-induced inflammation in mild asthmatic subjects. Respir Res 12:140
199. Timmer W, Leclerc V, Birraux G et al (2002) The new phosphodiesterase 4 inhibitor roflumilast is efficacious in exercise-induced asthma and leads to suppression of LPS-stimulated TNF-alpha ex vivo. J Clin Pharmacol 42:297–303
200. Bousquet J, Aubier M, Sastre J et al (2006) Comparison of roflumilast, an oral anti-inflammatory, with beclomethasone dipropionate in the treatment of persistent asthma. Allergy 61:72–78
201. Bateman ED, Izquierdo JL, Harnest U et al (2006) Efficacy and safety of roflumilast in the treatment of asthma. Ann Allergy Asthma Immunol 96:679–686
202. Holgate ST, Polosa R (2008) Treatment strategies for allergy and asthma. Nat Rev Immunol 8:218–230
203. Abramson, M.J., Puy, R.M. and Weiner, J.M. (2010), Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev. CD001186
204. Lin SY, Erekosima N, Kim JM et al (2013) Sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma: a systematic review. JAMA 309:1278–1288
205. Busse W, Corren J, Lanier BQ et al (2001) Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 108:184–190
206. Soler M, Matz J, Townley R et al (2001) The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 18:254–261
207. Humbert M, Beasley R, Ayres J et al (2005) Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 60:309–316
208. Hanania NA, Alpan O, Hamilos DL et al (2011) Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med 154:573–582
209. Walker, S., Monteil, M., Phelan, K., Lasserson, T.J. and Walters, E.H. (2006), Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst Rev. CD003559
210. Burch J, Griffin S, McKenna C et al (2012) Omalizumab for the treatment of severe persistent allergic asthma in children aged 6–11 years: a NICE single technology appraisal. Pharmacoeconomics 30:991–1004
211. Walker S, Burch J, McKenna C, Wright K, Griffin S, Woolacott N (2011) Omalizumab for the treatment of severe persistent allergic asthma in children aged 6–11 years. Health Technol Assess 15(Suppl 1):13–21
212. Jones J, Shepherd J, Hartwell D et al (2009) Omalizumab for the treatment of severe persistent allergic asthma. Health Technol Assess 13(Suppl 2):31–39
213. Diaz R, Charles Z, George E, Adler A (2013) NICE guidance on omalizumab for severe asthma. Lancet Respir Med 1:189–190
214. Rambasek TE, Lang DM, Kavuru MS (2004) Omalizumab: where does it fit into current asthma management? Cleve Clin J Med 71:251–261
215. Busse W, Buhl R, Fernandez Vidaurre C et al (2012) Omalizumab and the risk of malignancy: results from a pooled analysis. J Allergy Clin Immunol 129(983–989):e986
216. Rowe BH, Camargo CA Jr (2008) The role of magnesium sulfate in the acute and chronic management of asthma. Curr Opin Pulm Med 14:70–76
217. Song WJ, Chang YS (2012) Magnesium sulfate for acute asthma in adults: a systematic literature review. Asia Pac Allergy 2:76–85
218. Shan Z, Rong Y, Yang W et al (2013) Intravenous and nebulized magnesium sulfate for treating acute asthma in adults and children: a systematic review and meta-analysis. Respir Med 107:321–330
219. Fogarty A, Lewis SA, Scrivener SL et al (2003) Oral magnesium and vitamin C supplements in asthma: a parallel group randomized placebo-controlled trial. Clin Exp Allergy 33:1355–1359
220. Gontijo-Amaral C, Ribeiro MA, Gontijo LS, Condino-Neto A, Ribeiro JD (2007) Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial. Eur J Clin Nutr 61:54–60
221. Kazaks AG, Uriu-Adams JY, Albertson TE, Shenoy SF, Stern JS (2010) Effect of oral magnesium supplementation on measures of airway resistance and subjective assessment of asthma control and quality of life in men and women with mild to moderate asthma: a randomized placebo controlled trial. J Asthma 47:83–92
222. Mohammed S, Goodacre S (2007) Intravenous and nebulised magnesium sulphate for acute asthma: systematic review and meta-analysis. Emerg Med J 24:823–830
223. Torres S, Sticco N, Bosch JJ et al (2012) Effectiveness of magnesium sulfate as initial treatment of acute severe asthma in children, conducted in a tertiary-level university hospital: a randomized, controlled trial. Arch Argent Pediatr 110:291–296
224. Blitz M, Blitz S, Hughes R et al (2005) Aerosolized magnesium sulfate for acute asthma: a systematic review. Chest 128:337–344
225. Powell C, Dwan K, Milan SJ et al (2012) Inhaled magnesium sulfate in the treatment of acute asthma. Cochrane Database Syst Rev 12:CD003898
226. Villeneuve EJ, Zed PJ (2006) Nebulized magnesium sulfate in the management of acute exacerbations of asthma. Ann Pharmacother 40:1118–1124
227. Zervas E, Papatheodorou G, Psathakis K, Panagou P, Georgatou N, Loukides S (2003) Reduced intracellular Mg concentrations in patients with acute asthma. Chest 123:113–118
228. Hess DR, Fink JB, Venkataraman ST, Kim IK, Myers TR, Tano BD (2006) The history and physics of heliox. Respir Care 51:608–612
229. Fink JB (2006) Opportunities and risks of using heliox in your clinical practice. Respir Care 51:651–660
230. Kim IK, Saville AL, Sikes KL, Corcoran TE (2006) Heliox-driven albuterol nebulization for asthma exacerbations: an overview. Respir Care 51:613–618
231. Brandao DC, Britto MC, Pessoa MF et al (2011) Heliox and forward-leaning posture improve the efficacy of nebulized bronchodilator in acute asthma: a randomized trial. Respir Care 56:947–952
232. Alcoforado, L., Brandao, S., Rattes, C., et al. (2013), Evaluation of lung function and deposition of aerosolized bronchodilators carried by heliox associated with positive expiratory pressure in stable asthmatics: a randomized clinical trial. Respir Med (in press)
233. Bigham MT, Jacobs BR, Monaco MA et al (2010) Helium/oxygen-driven albuterol nebulization in the management of children with status asthmaticus: a randomized, placebo-controlled trial. Pediatr Crit Care Med 11:356–361
234. Colebourn CL, Barber V, Young JD (2007) Use of helium-oxygen mixture in adult patients presenting with exacerbations of asthma and chronic obstructive pulmonary disease: a systematic review. Anaesthesia 62:34–42
235. Kass JE, Castriotta RJ (1995) Heliox therapy in acute severe asthma. Chest 107:757–760
236. Kass JE, Terregino CA (1999) The effect of heliox in acute severe asthma: a randomized controlled trial. Chest 116:296–300
237. Ho AM, Lee A, Karmakar MK, Dion PW, Chung DC, Contardi LH (2003) Heliox vs air-oxygen mixtures for the treatment of patients with acute asthma: a systematic overview. Chest 123:882–890
238. Rodrigo, G., Pollack, C., Rodrigo, C. and Rowe, B.H. (2006) Heliox for nonintubated acute asthma patients. Cochrane Database Syst Rev. CD002884
239. Apter AJ (2013) Advances in adult asthma diagnosis and treatment in 2012: potential therapeutics and gene-environment interactions. J Allergy Clin Immunol 131:47–54
240. Barnes PJ (2006) New therapies for asthma. Trends Mol Med 12:515–520
241. Portelli M, Sayers I (2012) Genetic basis for personalized medicine in asthma. Expert Rev Respir Med 6:223–236
242. Pelaia G, Vatrella A, Maselli R (2012) The potential of biologics for the treatment of asthma. Nat Rev Drug Discov 11:958–972
243. Ingram JL, Kraft M (2012) IL-13 in asthma and allergic disease: asthma phenotypes and targeted therapies. J Allergy Clin Immunol 130:829–842, quiz 843–824
244. Corren J, Lemanske RF, Hanania NA et al (2011) Lebrikizumab treatment in adults with asthma. N Engl J Med 365:1088–1098
245. Woodruff PG, Modrek B, Choy DF et al (2009) T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med 180:388–395
246. Wenzel S, Ford L, Pearlman D et al (2013) Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 368:2455–2466
247. Haldar P, Brightling CE, Hargadon B et al (2009) Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 360:973–984
248. Pavord ID, Korn S, Howarth P et al (2012) Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 380:651–659
249. Beeh KM, Kanniess F, Wagner F et al (2013) The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent allergic asthma. J Allergy Clin Immunol 131:866–874
250. Desai D, Brightling C (2010) TNF-alpha antagonism in severe asthma? Recent Pat Inflamm Allergy Drug Discov 4:193–200
251. Matera MG, Calzetta L, Cazzola M (2010) TNF-alpha inhibitors in asthma and COPD: we must not throw the baby out with the bath water. Pulm Pharmacol Ther 23:121–128
252. Hahn DL, Grasmick M, Hetzel S, Yale S, AZMATICS (Azithromycin-Asthma Trial in Community Settings) Study Group (2012) Azithromycin for bronchial asthma in adults: an effectiveness trial. J Am Board Fam Med 25:442–459
253. Silva D, Couto M, Delgado L, Moreira A (2012) A systematic review of statin efficacy in asthma. J Asthma 49:885–894
254. Jat KR, Chawla D (2012) Ketamine for management of acute exacerbations of asthma in children. Cochrane Database Syst Rev 11:CD009293
255. Silverman RA, Foley F, Dalipi R, Kline M, Lesser M (2012) The use of rhDNAse in severely ill, non-intubated adult asthmatics refractory to bronchodilators: a pilot study. Respir Med 106:1096–1102